You are here:

sufentanil citrate (Zalviso)

Advice

in the absence of a submission from the holder of the marketing authorisation

sufentanil citrate (Zalviso ®) is not recommended for use within NHS Scotland.

Indication under review: Management of acute moderate to severe post-operative pain in adult patients.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: sufentanil citrate (Zalviso)
SMC Drug ID: 1270/17
Manufacturer: GrĂ¼nenthal Ltd
Indication: management of acute moderate to severe post-operative pain in adult patients.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 7 August 2017

Back